AIM ImmunoTech expands at-the-market stock program
AIM ImmunoTech Inc. entered into Amendment No. 1 to its Equity Distribution Agreement with Maxim Group LLC, which serves as its exclusive sales agent for an at-the-market stock offering.
Rhea-AI Filing Summary
AIM ImmunoTech Inc. entered into Amendment No. 1 to its Equity Distribution Agreement with Maxim Group LLC, which serves as its exclusive sales agent for an at-the-market stock offering. The original agreement covered issuance and sale of up to $3,000,000 of common shares.
The amendment removes the limitation on the amount of shares that may be sold under the agreement, allowing additional sales under the company’s effective shelf registration statement on Form S-3 and related prospectus. AIM is also filing a new prospectus supplement to increase the number of shares that may be offered and sold through this at-the-market program.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 1.01, 9.01
2 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Previous ATM capacity: $3,000,000 of common stock
1 metrics
Previous ATM capacity
$3,000,000 of common stock
Maximum amount of shares under original Equity Distribution Agreement
Key Terms
Equity Distribution Agreement, at-the-market public offering, shelf registration statement on Form S-3, prospectus supplement, +1 more
5 terms
Equity Distribution Agreement financial
"entered into Amendment No. 1 (the “Amendment”) to that certain Equity Distribution Agreement dated April 1, 2025"
An equity distribution agreement is a formal plan between a company and financial institutions to sell newly issued shares of the company's stock to investors over a period of time. It helps the company raise money gradually, similar to filling a container with water in stages, rather than all at once. For investors, it provides an organized way to buy shares and can influence the stock's supply and price.
at-the-market public offering financial
"from time to time, in an at-the-market public offering (the “Offering”)"
shelf registration statement on Form S-3 regulatory
"pursuant the Company’s shelf registration statement on Form S-3 (File No. 333-286319)"
A shelf registration statement on Form S-3 is a pre-approved filing with the Securities and Exchange Commission that lets an eligible public company register securities in advance and sell them later in one or more offerings without repeating the full registration process. Think of it like a pre-approved funding line: it gives management the flexibility to raise capital quickly when market conditions are right, a move that can affect share supply, dilution and investor returns, so investors monitor it as a signal of potential financing activity.
prospectus supplement regulatory
"filing a supplement to the prospectus supplement with the Securities and Exchange Commission"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
emerging growth company regulatory
"Emerging growth company Securities registered pursuant to Section 12(b) of the Act"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What agreement did AIM (AIM) amend on April 10, 2026?
AIM ImmunoTech Inc. amended its Equity Distribution Agreement with Maxim Group LLC. This agreement appoints Maxim as exclusive sales agent for issuing and selling AIM common stock through an at-the-market offering program.
How much stock was AIM (AIM) originally able to sell under the Equity Distribution Agreement?
The original Equity Distribution Agreement covered issuance and sale of up to $3,000,000 of AIM common stock. This figure defined the previous maximum capacity of the company’s at-the-market stock offering program with Maxim Group LLC.
What change does the new amendment make to AIM’s (AIM) at-the-market program?
The amendment removes the prior limitation on the amount of shares that may be sold under the Equity Distribution Agreement. This allows AIM to sell additional common shares through its existing at-the-market offering structure with Maxim Group LLC.
Who is acting as AIM’s (AIM) exclusive sales agent in the at-the-market offering?
Maxim Group LLC is acting as AIM ImmunoTech Inc.’s exclusive sales agent. Under the Equity Distribution Agreement, Maxim arranges the issuance and sale of AIM’s common stock in at-the-market transactions pursuant to the company’s shelf registration.
AI-generated analysis. How Rhea-AI works. Not financial advice.
